• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

    11/17/25 8:17:05 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORIC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    ORIC Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    68622P109

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    The Column Group II, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,540,777.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,540,777.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,540,777.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   All such shares are held of record by TCG II LP (as defined in Item 2(a) below). TCG II GP LP (as defined in Item 2(a) below) is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Based on 97,122,987 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 12, 2025 (the "Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    The Column Group II GP, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,540,777.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,540,777.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,540,777.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.6 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:   All such shares are held of record by TCG II LP. TCG II GP LP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Based on 97,122,987 shares of Common Stock outstanding as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    David V Goeddel
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    86,716.00
    6Shared Voting Power

    3,540,777.00
    7Sole Dispositive Power

    86,716.00
    8Shared Dispositive Power

    3,540,777.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,627,493.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   3,540,777 of such shares are held of record by TCG II LP. TCG II GP LP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Based on 97,122,987 shares of Common Stock outstanding as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Peter Svennilson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SWEDEN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    103,341.00
    6Shared Voting Power

    3,540,777.00
    7Sole Dispositive Power

    103,341.00
    8Shared Dispositive Power

    3,540,777.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,644,118.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:   3,540,777 of such shares are held of record by TCG II LP. TCG II GP LP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and David Goeddel are the managing partners of TCG II LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Based on 97,122,987 shares of Common Stock outstanding as reported by the Issuer in its Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ORIC Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 3 ("Amendment No. 3") amends and supplements the Schedule 13G initially filed with the Commission on February 16, 2021, as amended by Amendment No. 1 filed with the Commission on February 11, 2022 (collectively, the "Original Schedule 13G") and Amendment No. 2 filed with the Commission on November 14, 2024 and is being filed by The Column Group II, LP ("TCG II LP"), The Column Group II GP, LP ("TCG II GP LP" and together with TCG II LP, the "Reporting Entities") and Peter Svennilson ("Svennilson") and David Goeddel ("Goeddel" and together with Svennilson, the "Managing Individuals"). The Reporting Entities and the Managing Individuals collectively are referred to as the "Reporting Persons". The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act was filed as Exhibit 1 to the Original Schedule 13G . Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 3 have the meanings ascribed to them in the Original Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is c/o The Column Group, 1 Letterman Drive, Building D, Suite M-900, San Francisco, CA 94129.
    (c)Citizenship:

    Each of TCG II LP and TCG II GP LP is a limited partnership organized under the laws of the State of Delaware. Goeddel is a citizen of the United States of America and Svennilson is a citizen of Sweden.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    68622P109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Column Group II, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:11/14/2025
     
    The Column Group II GP, LP
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:11/14/2025
     
    David V Goeddel
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:11/14/2025
     
    Peter Svennilson
     
    Signature:/s/ James Evangelista, Attorney-in-Fact
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:11/14/2025
    Get the next $ORIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORIC

    DatePrice TargetRatingAnalyst
    11/20/2025$25.00Outperform
    Evercore ISI
    11/18/2025Peer Perform
    Wolfe Research
    9/4/2025$18.00Buy
    Guggenheim
    7/8/2025$15.00Buy
    Ladenburg Thalmann
    10/31/2024$20.00Overweight
    Wells Fargo
    9/6/2024$20.00Buy
    Stifel
    2/23/2024Overweight
    Cantor Fitzgerald
    9/22/2023$8.00Outperform
    Wedbush
    More analyst ratings

    $ORIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Piscitelli Dominic exercised 11,000 shares at a strike of $4.36 and sold $159,719 worth of shares (11,000 units at $14.52) (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    10/8/25 5:37:17 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Chacko Jacob sold $461,520 worth of shares (37,461 units at $12.32), decreasing direct ownership by 7% to 531,419 units (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    10/8/25 5:35:33 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heyman Richard A. exercised 32,800 shares at a strike of $1.69, increasing direct ownership by 262% to 45,300 units (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    10/3/25 7:18:01 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

    Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiat

    11/13/25 4:10:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

    Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions were observed in 76% of patients and ctDNA clearance was observed in 59% of patients, underscoring potential for long-term treatment and survival benefit PSA responses and ctDNA reductions were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide or with darolutamide Both combination regimens continue to demonstrate a safety and tolerability profile compatible with long-term dosing, with the vast majority of adverse events Grade 1 or 2 and consist

    11/13/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 3, 2025 (the "Grant Date"), ORIC granted a total of 18,400 non-qualified stock options and 3,000 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The st

    11/7/25 4:30:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on ORIC Pharmaceuticals with a new price target

    Evercore ISI initiated coverage of ORIC Pharmaceuticals with a rating of Outperform and set a new price target of $25.00

    11/20/25 8:08:07 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on ORIC Pharmaceuticals

    Wolfe Research initiated coverage of ORIC Pharmaceuticals with a rating of Peer Perform

    11/18/25 8:25:41 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim resumed coverage on ORIC Pharmaceuticals with a new price target

    Guggenheim resumed coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $18.00

    9/4/25 9:07:21 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

    SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/17/25 8:17:05 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

    SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/13/25 6:15:36 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oric Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

    11/13/25 4:25:15 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director You Angie bought $262,899 worth of shares (28,000 units at $9.39) (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    6/23/25 8:05:17 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Financials

    Live finance-specific insights

    View All

    ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

    Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC       PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated

    5/28/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode req

    5/27/25 8:00:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

    Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11

    12/11/23 12:00:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Leadership Updates

    Live Leadership Updates

    View All

    ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

    Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiat

    11/13/25 4:10:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t

    8/18/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

    Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected

    2/18/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:54:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:47:31 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:14:58 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care